Identification of Novel Compounds Inhibiting Chikungunya Virus-Induced Cell Death by High Throughput Screening of a Kinase Inhibitor Library

PLoS Neglected Tropical Diseases

Volumn 7, Issue 10, 2013, Pages

  Cruz, Deu John M ^a   Bonotto, Rafaela M ^a,b   Gomes, Rafael G B ^a,c   da Silva, Camila T ^a,d   Taniguchi, Juliana B ^a,e   No, Joo Hwan ^a   Lombardot, Benoit ^f   Schwartz, Olivier ^g   Hansen, Michael A E ^f   Freitas Junior, Lucio H ^a,h  

^a Institute Pasteur Korea   (South Korea)

^b UNIVERSIDADE FEEVALE   (Brazil)

^c FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^d UNIVERSIDADE ESTADUAL DO RIO GRANDE DO SUL   (Brazil)

^e SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^f Image Mining Group (IMG)   (South Korea)

^g INSTITUT PASTEUR   (France)

^h BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BAFILOMYCIN A1; BENZOFURAN; CHLOROQUINE; CHLORPROMAZINE; MYCOPHENOLIC ACID; PHOSPHOTRANSFERASE INHIBITOR; PYRROLOPYRIDINE; RESAZURIN; THIAZOLE CARBOXAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CELL VIABILITY; CHEMICAL STRUCTURE; CHIKUNGUNYA; CONTROLLED STUDY; CYTOTOXICITY; ELECTRONICS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; INFECTION CONTROL; NUCLEOTIDE SEQUENCE; PROCESS OPTIMIZATION; QUALITY CONTROL; VALIDATION PROCESS; VIRUS REPLICATION; VIRUS TITRATION;

ALPHAVIRUS INFECTIONS; ANTIVIRAL AGENTS; CELL DEATH; CELL LINE; CELL SURVIVAL; CHIKUNGUNYA VIRUS; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; OPTICAL IMAGING; OXAZINES; OXIDATION-REDUCTION; PROTEIN KINASE INHIBITORS; STAINING AND LABELING; XANTHENES;

EID: 84887273261     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002471     Document Type: Article

References (81)

1. Griffin DE (2007) Alphaviruses. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. pp. 1023-1067.
2. Khan AH, Morita K, Parquet Md Mdel C, Hasebe F, Mathenge EG, et al. (2002) Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site. J Gen Virol 83: 3075-3084.
3. Strauss JH, Strauss EG, (1994) The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58: 491-562.
4. Higashi N, Matsumoto A, Tabata K, Nagatomo Y, (1967) Electron microscope study of development of Chikungunya virus in green monkey kidney stable (VERO) cells. Virology 33: 55-69.
5. Simizu B, Yamamoto K, Hashimoto K, Ogata T, (1984) Structural proteins of Chikungunya virus. J Virol 51: 254-258.
6. Dupuis-Maguiraga L, Noret M, Brun S, Le Grand R, Gras G, et al. (2012) Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia. PLoS Negl Trop Dis 6: e1446 doi:10.1371/journal.pntd.0001446.
7. Martin E, Moutailler S, Madec Y, Failloux AB, (2010) Differential responses of the mosquito Aedes albopictus from the Indian Ocean region to two chikungunya isolates. BMC Ecol 10: 8 doi:10.1186/1472-6785-10-8.
8. Ali Ou Alla S, Combe B, (2011) Arthritis after infection with Chikungunya virus. Best Pract Res Clin Rheumatol 25: 337-346 doi:10.1016/j.berh.2011.03.005.
9. Ross RW, (1956) The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond) 54: 177-191.
10. Chia PY, Ng MML, Chu JJH (2010) Chikungunya fever: A review of a re-emerging mosquito-borne infectious disease and the current status. In: Méndez-Vilas A, editor. Current Research, Technology and Education Topics in Applied Microbiology and Microbial Biotechnology. Badajoz: Formatex Research Center. pp. 597-606.
11. Tong JC, Simarmata D, Lin RT, Renia L, Ng LF, (2010) HLA class I restriction as a possible driving force for Chikungunya evolution. PLoS One 5: e9291 doi:10.1371/journal.pone.0009291.
12. Enserink M, (2007) Infectious diseases. Chikungunya: no longer a third world disease. Science 318: 1860-1861 doi:10.1126/science.318.5858.1860.
13. Kamath S, Das AK, Parikh FS, (2006) Chikungunya. J Assoc Physicians India 54: 725-726.
14. Her Z, Kam YW, Lin RT, Ng LF, (2009) Chikungunya: a bending reality. Microbes Infect 11: 1165-1176 doi:10.1016/j.micinf.2009.09.004.
15. Powers AM, Logue CH, (2007) Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol 88: 2363-2377 doi:10.1099/vir.0.82858-0.
16. Weaver SC, Barrett AD, (2004) Transmission cycles, host range, evolution and emergence of arboviral disease. Nat Rev Microbiol 2: 789-801 doi:10.1038/nrmicro1006.
17. WHO (2008) Guidelines on clinical management of chikungunya fever. New Delhi: World Health Organization Regional Office for South-East Asia. 18 p.
18. de Andrade DC, Jean S, Clavelou P, Dallel R, Bouhassira D, (2010) Chronic pain associated with the Chikungunya Fever: long lasting burden of an acute illness. BMC Infect Dis 10: 31 doi:10.1186/1471-2334-10-31.
19. Larrieu S, Pouderoux N, Pistone T, Filleul L, Receveur MC, et al. (2010) Factors associated with persistence of arthralgia among Chikungunya virus-infected travellers: report of 42 French cases. J Clin Virol 47: 85-88 doi:10.1016/j.jcv.2009.11.014.
20. Staples JE, Breiman RF, Powers AM, (2009) Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis 49: 942-948 doi:10.1086/605496.
21. Reiter P, Fontenille D, Paupy C, (2006) Aedes albopictus as an epidemic vector of chikungunya virus: another emerging problem? Lancet Infect Dis 6: 463-464 doi:10.1016/S1473-3099(06)70531-X.
22. Bessaud M, Peyrefitte CN, Pastorino BA, Tock F, Merle O, et al. (2006) Chikungunya virus strains, Reunion Island outbreak. Emerg Infect Dis 12: 1604-1606 doi:10.3201/eid1210.060596.
23. Kam YW, Ong EK, Renia L, Tong JC, Ng LF, (2009) Immuno-biology of Chikungunya and implications for disease intervention. Microbes Infect 11: 1186-1196 doi:10.1016/j.micinf.2009.09.003.
24. McClain DJ, Pittman PR, Ramsburg HH, Nelson GO, Rossi CA, et al. (1998) Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis 177: 634-641.
25. Briolant S, Garin D, Scaramozzino N, Jouan A, Crance JM, (2004) In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res 61: 111-117.
26. Delogu I, de Lamballerie X, (2011) Chikungunya disease and chloroquine treatment. J Med Virol 83: 1058-1059 doi:10.1002/jmv.22019.
27. Delogu I, Pastorino B, Baronti C, Nougairede A, Bonnet E, et al. (2011) In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res 90: 99-107 doi:10.1016/j.antiviral.2011.03.182.
28. Ravichandran R, Manian M, (2008) Ribavirin therapy for Chikungunya arthritis. J Infect Dev Ctries 2: 140-142.
29. Pohjala L, Utt A, Varjak M, Lulla A, Merits A, et al. (2011) Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays. PLoS One 6: e28923 doi:10.1371/journal.pone.0028923.
30. Lucas-Hourani M, Lupan A, Despres P, Thoret S, Pamlard O, et al. (2013) A phenotypic assay to identify Chikungunya virus inhibitors targeting the nonstructural protein nsP2. J Biomol Screen 18: 172-179 doi:10.1177/1087057112460091.
31. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, et al. (2011) Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 10: 188-195 doi:10.1038/nrd3368.
32. Abu-Amero KK, Bosley TM, (2005) Detection of mitochondrial respiratory dysfunction in circulating lymphocytes using resazurin. Arch Pathol Lab Med 129: 1295-1298 doi:[];10.1043/1543-2165(2005)129[1295:DOMRDI]2.0.CO;2.
33. O'Brien J, Wilson I, Orton T, Pognan F, (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267: 5421-5426.
34. Cruz DJ, Koishi AC, Taniguchi JB, Li X, Milan Bonotto R, et al. (2013) High content screening of a kinase-focused library reveals compounds broadly-active against dengue viruses. PLoS Negl Trop Dis 7: e2073 doi:10.1371/journal.pntd.0002073.
35. Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, et al. (2006) Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 3: e263 doi:10.1371/journal.pmed.0030263.
36. Siqueira-Neto JL, Song OR, Oh H, Sohn JH, Yang G, et al. (2010) Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl Trop Dis 4: e675 doi:10.1371/journal.pntd.0000675.
37. Nakao E, Hotta S, (1973) Immunogenicity of purified, inactivated chikungunya virus in monkeys. Bull World Health Organ 48: 559-562.
38. Lotufo RdA, Falc AX, (2002) Zampirolli FA, (2002) IFT-Watershed from Gray-Scale Marker. Proceedings of the 15th Brazilian Symposium on Computer Graphics and Image Processing:. IEEE Computer Society pp. 146-152.
39. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
40. Harris CJ, Hill RD, Sheppard DW, Slater MJ, Stouten PF, (2011) The design and application of target-focused compound libraries. Comb Chem High Throughput Screen 14: 521-531.
41. Backman TW, Cao Y, Girke T, (2011) ChemMine tools: an online service for analyzing and clustering small molecules. Nucleic Acids Res 39: W486-491 doi:10.1093/nar/gkr320.
42. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, et al. (2004) Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 101: 2536-2541.
43. Salvador B, Zhou Y, Michault A, Muench MO, Simmons G, (2009) Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology 393: 33-41 doi:10.1016/j.virol.2009.07.013.
44. Solignat M, Gay B, Higgs S, Briant L, Devaux C, (2009) Replication cycle of chikungunya: a re-emerging arbovirus. Virology 393: 183-197 doi:10.1016/j.virol.2009.07.024.
45. McMillian MK, Li L, Parker JB, Patel L, Zhong Z, et al. (2002) An improved resazurin-based cytotoxicity assay for hepatic cells. Cell Biol Toxicol 18: 157-173.
46. Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, et al. (2007) Characterization of reemerging chikungunya virus. PLoS Pathog 3: e89 doi:10.1371/journal.ppat.0030089.
47. Bernard E, Solignat M, Gay B, Chazal N, Higgs S, et al. (2010) Endocytosis of chikungunya virus into mammalian cells: role of clathrin and early endosomal compartments. PLoS One 5: e11479 doi:10.1371/journal.pone.0011479.
48. Tsetsarkin K, Higgs S, McGee CE, De Lamballerie X, Charrel RN, et al. (2006) Infectious clones of Chikungunya virus (La Reunion isolate) for vector competence studies. Vector Borne Zoonotic Dis 6: 325-337 doi:10.1089/vbz.2006.6.325.
49. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S, (2011) Lysosomotropic agents as HCV entry inhibitors. Virol J 8: 163 doi:10.1186/1743-422X-8-163.
50. Sweeney MJ, (1977) Mycophenolic acid and its mechanism of action in cancer and psoriasis. Jpn J Antibiot 30 Suppl: 85-92.
51. Thiboutot MM, Kannan S, Kawalekar OU, Shedlock DJ, Khan AS, et al. (2010) Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis 4: e623 doi:10.1371/journal.pntd.0000623.
52. Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R, et al. (1993) Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 167: 932-937.
53. Brighton SW, (1984) Chloroquine phosphate treatment of chronic Chikungunya arthritis. An open pilot study. S Afr Med J 66: 217-218.
54. De Lamballerie X, Boisson V, Reynier JC, Enault S, Charrel RN, et al. (2008) On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 8: 837-839 doi:10.1089/vbz.2008.0049.
55. Wu JZ, Lin CC, Hong Z, (2003) Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. J Antimicrob Chemother 52: 543-546 doi:10.1093/jac/dkg405.
56. John CK, (1939) Place of the Methylene Blue and Resazurin Reduction Tests in a Milk Control Program. Am J Public Health Nations Health 29: 239-247.
57. Avakian AO, (1969) [Sanitary-bacteriological assessment of raw, semi-finished and ready-to-eat meat and fish products, by the resazurin test]. Vopr Pitan 28: 64-65.
58. Taneja NK, Tyagi JS, (2007) Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. J Antimicrob Chemother 60: 288-293 doi:10.1093/jac/dkm207.
59. Webster D, Lee TD, Moore J, Manning T, Kunimoto D, et al. (2010) Antimycobacterial screening of traditional medicinal plants using the microplate resazurin assay. Can J Microbiol 56: 487-494 doi:10.1139/w10-035.
60. Duarte M, Giordani RB, De Carli GA, Zuanazzi JA, Macedo AJ, et al. (2009) A quantitative resazurin assay to determinate the viability of Trichomonas vaginalis and the cytotoxicity of organic solvents and surfactant agents. Exp Parasitol 123: 195-198 doi:10.1016/j.exppara.2009.07.002.
61. Sykes ML, Avery VM, (2009) Development of an Alamar Blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Am J Trop Med Hyg 81: 665-674 doi:10.4269/ajtmh.2009.09-0015.
62. Monteiro MC, de la Cruz M, Cantizani J, Moreno C, Tormo JR, et al. (2012) A new approach to drug discovery: high-throughput screening of microbial natural extracts against Aspergillus fumigatus using resazurin. J Biomol Screen 17: 542-549 doi:10.1177/1087057111433459.
63. Page B, Page M, Noel C, (1993) A new fluorometric assay for cytotoxicity measurements in-vitro. Int J Oncol 3: 473-476.
64. Uzunoglu S, Karaca B, Atmaca H, Kisim A, Sezgin C, et al. (2010) Comparison of XTT and Alamar blue assays in the assessment of the viability of various human cancer cell lines by AT-101 (-/- gossypol). Toxicol Mech Methods 20: 482-486 doi:10.3109/15376516.2010.508080.
65. Lewis M, Weaver CD, McClain MS, (2010) Identification of Small Molecule Inhibitors of Clostridium perfringens epsilon-Toxin Cytotoxicity Using a Cell-Based High-Throughput Screen. Toxins (Basel) 2: 1825-1847 doi:10.3390/toxins2071825.
66. Kim MJ, Pal S, Tak YK, Lee KH, Yang TK, et al. (2007) Determination of the dose-depth distribution of proton beam using resazurin assay in vitro and diode laser-induced fluorescence detection. Anal Chim Acta 593: 214-223 doi:10.1016/j.aca.2007.05.009.
67. Rampersad SN, (2012) Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors (Basel) 12: 12347-12360 doi:10.3390/s120912347.
68. Couderc T, Chretien F, Schilte C, Disson O, Brigitte M, et al. (2008) A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 4: e29 doi:10.1371/journal.ppat.0040029.
69. Ozden S, Huerre M, Riviere JP, Coffey LL, Afonso PV, et al. (2007) Human muscle satellite cells as targets of Chikungunya virus infection. PLoS One 2: e527 doi:10.1371/journal.pone.0000527.
70. Abere B, Wikan N, Ubol S, Auewarakul P, Paemanee A, et al. (2012) Proteomic analysis of chikungunya virus infected microgial cells. PLoS One 7: e34800 doi:10.1371/journal.pone.0034800.
71. Her Z, Malleret B, Chan M, Ong EK, Wong SC, et al. (2010) Active infection of human blood monocytes by Chikungunya virus triggers an innate immune response. J Immunol 184: 5903-5913 doi:10.4049/jimmunol.0904181.
72. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, et al. (2010) Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 184: 5914-5927 doi:10.4049/jimmunol.0900255.
73. Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, et al. (2010) Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 120: 894-906 doi:10.1172/JCI40104.
74. Krejbich-Trotot P, Denizot M, Hoarau JJ, Jaffar-Bandjee MC, Das T, et al. (2011) Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses. Faseb J 25: 314-325 doi:10.1096/fj.10-164178.
75. White LK, Sali T, Alvarado D, Gatti E, Pierre P, et al. (2011) Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff. J Virol 85: 606-620 doi:10.1128/JVI.00767-10.
76. Rathore AP, Ng ML, Vasudevan SG, (2013) Differential unfolded protein response during Chikungunya and Sindbis virus infection: CHIKV nsP4 suppresses eIF2alpha phosphorylation. Virol J 10: 36 doi:10.1186/1743-422X-10-36.
77. Lai E, Teodoro T, Volchuk A, (2007) Endoplasmic reticulum stress: signaling the unfolded protein response. Physiology (Bethesda) 22: 193-201 doi:10.1152/physiol.00050.2006.
78. Krejbich-Trotot P, Gay B, Li-Pat-Yuen G, Hoarau JJ, Jaffar-Bandjee MC, et al. (2011) Chikungunya triggers an autophagic process which promotes viral replication. Virol J 8: 432 doi:10.1186/1743-422X-8-432.
79. Joubert PE, Werneke SW, de la Calle C, Guivel-Benhassine F, Giodini A, et al. (2012) Chikungunya virus-induced autophagy delays caspase-dependent cell death. J Exp Med 209: 1029-1047 doi:10.1084/jem.20110996.
80. Furuya T, Kim M, Lipinski M, Li J, Kim D, et al. (2010) Negative regulation of Vps34 by Cdk mediated phosphorylation. Mol Cell 38: 500-511 doi:10.1016/j.molcel.2010.05.009.
81. Schwartz O, Albert ML, (2010) Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol 8: 491-500 doi:10.1038/nrmicro2368.